Chronic beta adrenergic blockade in arterial hypertension. Hemodynamic influences of dihydralazine and dynamic exercise and clinical effects of combined treatment.
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000526:Alprenolol / Q000008:administration & dosage; D000605:Amino Alcohols / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004357:Drug Synergism; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption / Q000187:drug effects; D026741:Physical Therapy Modalities; D011187:Posture; D011724:Pyridazines / Q000008:administration & dosage*; D013565:Sympatholytics / Q000008:administration & dosage*; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D011724:Pyridazines; D013565:Sympatholytics; D000526:Alprenolol